

DESCRIPTION

Source Chinese Hamster Ovary cell line, CHO-derived
 Ser293-His431
 Accession # P18075

N-terminal Sequence Analysis Ser293

Structure / Form Disulfide-linked homodimer

Predicted Molecular Mass 15.7 kDa (monomer)

SPECIFICATIONS

SDS-PAGE 18-20 kDa, reducing conditions

Activity Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Nakamura, K. *et al.* (1999) Exp. Cell Res. **250**:351.
 The ED₅₀ for this effect is typically 0.1-0.6 µg/mL.

Endotoxin Level <0.01 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 100 µg/mL in sterile 4 mM HCl containing at least 0.1% human or bovine serum albumin.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Bone morphogenetic protein 7 (BMP-7), also known as osteogenic protein 1 (OP-1), is a widely expressed TGF-β superfamily member with important functions during embryogenesis, in the adult, and in disease (1, 2). Human BMP-7 is synthesized with a 29 amino acid (aa) signal sequence, a 263 aa propeptide, and a 139 aa growth factor domain (3, 4). The growth factor domain of human BMP-7 shares 98% aa sequence identity with mouse and rat BMP-7. The BMP-7 propeptide is cleaved intracellularly but often remains associated with the mature C-terminus. Based on in vivo and in vitro studies, BMP-7 has the potential to be secreted as a disulfide-linked mature homodimer, or particularly as a heteromeric complex that consists of two propeptides noncovalently associated with a mature disulfide-linked homodimer (5, 6). The presence of the propeptides in BMP-7 appears to stabilize the molecule and provide a docking mechanism for extracellular storage on molecules such as fibrillin-1 and -2 (5, 6). The propeptides themselves do not impart latency to the complex. BMP-7 binding to type II receptors rapidly displaces the prodomain:mature molecule interaction and has no effect on activity. But it is suggested that immobilized BMP-7 (via prodomain:fibrillin) is inactive, allowing for possible long-term storage of the molecule (6). BMP-7 interacts with the type 2 receptors Activin RIIA, Activin RIIIB, and BMPRII and the type 1 receptors Activin RIA, BMPRII, and BMPRII (2, 6). BMP-7 may also be processed into a disulfide-linked heterodimer with either BMP-2 or BMP-4. Such complexes may show increased potency and range of activity compared to BMP-7 homodimers (7-9). BMP-7 plays a role in a variety of organ systems. It promotes new bone formation and nephron development (10, 11), inhibits the branching of prostate epithelium (12), and antagonizes epithelial-mesenchymal transition (EMT) (13-15). In pathological conditions, BMP-7 inhibits tumor growth and metastasis (14), ameliorates fibrotic damage in nephritis (13), and promotes neuroregeneration following brain ischemia (16).

References:

1. Chen, D. *et al.* (2004) Growth Factors **22**:233.
2. Kishigami, S. and Y. Mishina (2005) Cytokine Growth Factor Rev. **16**:265.
3. Ozkaynak, E. *et al.* (1990) EMBO J. **9**:2085.
4. Celeste, A.J. *et al.* (1990) Proc. Natl. Acad. Sci. **87**:9843.
5. Gregory, K.E. *et al.* (2005) J. Biol. Chem. **280**:27970.
6. Sengle, G. *et al.* (2008) J. Mol. Biol. **381**:1025.
7. Israel, D.I. *et al.* (1996) Growth Factors **13**:291.
8. Aono, A. *et al.* (1995) Biochem. Biophys. Res. Commun. **210**:670.
9. Nishimatsu, S. and G.H. Thomsen (1998) Mech. Dev. **74**:75.
10. Sampath, T.K. *et al.* (1992) J. Biol. Chem. **267**:20352.
11. Kazama, I. *et al.* (2008) J. Am. Soc. Nephrol. **19**:2181.
12. Grishina, I.B. *et al.* (2005) Dev. Biol. **288**:334.
13. Zeisberg, M. *et al.* (2003) Nat. Med. **9**:964.
14. Buijs, J.T. *et al.* (2007) Am. J. Pathol. **171**:1047.
15. Yu, M.-A. *et al.* (2009) J. Am. Soc. Nephrol. **20**:567.
16. Chou, J. *et al.* (2006) J. Neurol. Sci. **240**:21.